RETRACTED ARTICLE: Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis

Zhai, Jin-Hai; Gu, Wenchao; Xu, Xiaolin; Wu, Jiang; Hu, Xuejun; Hou, Kezuo

doi:10.1007/s13277-014-2251-z

Cited by 5 publications

(3 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have found that high CD133 expression is associated with decreased survival of patients with colorectal cancer and lung cancer [11,12]. Other studies found that CD133 expression may be positively correlated with poorer prognosis in cancer patients treated with chemoradiotherapy [43]. Thus, findings from previous studies suggest that CD133 expression has important roles in the progression of cancers.…”

Section: Discussionmentioning

confidence: 86%

High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma

Zhang

Chen

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

The CD133 antigen has been identified as a putative stem cell marker in gliomas. However, the prognostic significance of CD133 expression in glioblastoma patients remained controversial. A meta-analysis of published data was performed to comprehensively assess the prognostic role of CD133 expression in glioblastoma patients. Publications assessing the prognostic significance of CD133 expression in glioblastoma patients were identified in PubMed, Embase, and Web of Science up to November 2014. The pooled hazard ratio (HR) with 95% confidence interval (95% CI) was calculated using meta-analysis to evaluate the prognostic significance of CD133 expression in glioblastoma. Ten studies with a total of 715 glioblastoma patients were included into the meta-analysis. Overall, high CD133 expression was associated with poorer overall survival in patients with glioblastoma (HR = 1.96, 95% CI 1.46-2.64, P < 0.001). In addition, high CD133 expression was also associated with poorer progression-free survival in patients with glioblastoma (HR = 2.03, 95% CI 1.43-2.88, P < 0.001). Meta-analyses of studies with high quality showed that high CD133 expression was associated with both poorer overall survival (HR = 2.39, 95% CI 1.77-3.23, P < 0.001) and poorer progression-free survival (HR = 2.17, 95% CI 1.60-2.94, P < 0.001) in patients with glioblastoma. Meta-analysis of studies with adjusted estimates further showed that high CD133 expression was an independent prognostic factor of glioblastoma. High CD133 expression is associated with worse prognosis in patients with glioblastoma. More prospective studies with well-design are needed to confirm this finding.

show abstract

Section: Discussionmentioning

confidence: 86%

High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma

Zhang

Chen

et al. 2015

Mol Neurobiol

View full text Add to dashboard Cite

show abstract

“…CD133, one of the prognostic indicators for colorectal cancer, is a widely-applied tumor stem cell surface marker for colorectal cancer at present (Yao et al, 2014;Zheng et al, 2014). The studies found that the overall survival of patients with high expression of CD133 was markedly lower than those with low expression in the tumors, such as pancreatic cancer and lung cancer (Chen et al, 2014;Zhai et al, 2014;Tan et al, 2014). Wang et al studied the relationship between CD133 expression and prognosis in non-small cell lung cancer (NSCLC), and the results showed that CD133 was only related to tumor differentiated degrees and histological types instead of other clinicopathological features and diseasefree survival (Wang et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer

Guo²,

Yang³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: To explore the relationship between CXCR4, CD133 co-expression and clinicopathological features as well as prognosis of patients with phase Ⅱ~Ⅲ colon cancer. Materials and Methods: Forty-nine paraffin-embedded samples of tumor tissue and epithelial tissue adjacent to cancer were collected from patients with colon cancer undergoing radical surgery in Baotou Cancer Hospital from January, 2010 to June, 2011. CXCR4 and CD133 expression was detected using immunohistochemistry and its relationship with clinicopathological features and the 3-year survival rate was analyzed. Results: In the tumor tissue and colonic epithelial tissue adjacent to cancer, the positive expression rates of CXCR4 were respectively 61.2% (30/49) and 8.16% (4/49), while those of CD133 being 36.7% (18/49) and 6.12% (3/49). CXCR4 and CD133 expression in tumor tissue was not related to patient age, gender, primary focal sites, tumor size, TNM staging, histological type, tumor infiltration depth and presence or absence of lymphatic metastasis, but CXCR4 and CD133 co-expression was associated with TNM staging and lymphatic metastasis. The 3-year survival rate of patients with CXCR4 and CD133 co-expression was 27.3% (3/11), and that of the remainderwas 76.3% (29/38), the difference being significant (χ 2 =7.0206, p=0.0081). Conclusions: CXCR4 and CD133 co-expression may be a risk factor for poor prognosis of patients with stage Ⅱ~Ⅲ colon cancer.

show abstract

“…A very recent meta-analysis carried out in 470 patients affected by different solid tumours treated with chemoradiotherapy assessed the prognostic impact of CD133 expression (28). The analysis pointed out that CD133 expression positively correlated with poorer progression-free and overall survival.…”

Section: Discussionmentioning

confidence: 99%

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells

Napoletano

Bellati²,

Ruscito

et al. 2016

View full text Add to dashboard Cite

Abstract. Background: Cancer stem cells (CSCs) are tumour-initiating cells with self-renewal properties and chemo/radio-resistance. Regulatory T-cells (Tregs) influenceVulvar cancer is an uncommon gynaecological malignancy; approximately 4,850 new cases of vulvar cancer and 1,030 deaths from this disease were projected for the United States in 2014 (1). Most patients are elderly, with a peak of incidence in the eighth decade; nearly 30% are diagnosed at international Federation of Gynaecology and Obstetrics (FIGO) stage III or IV with a 5-year overall survival of 43% and 13%, respectively (2). Although representing a rare disease of elderly women with a current incidence of 2-3 per 100,000 women and a median age of 65-70 years old, vulvar cancer has shown an increasing incidence with concurrently decreasing median age of 55-60 years at onset over the past few decades (1, 3).The standard treatment of vulvar cancer includes radical surgery and adjuvant radiotherapy in selected cases. Considering the median age of these patients, clinical and pathological prognostic factors are constantly being explored in order to minimize unnecessary treatments. Furthermore, new molecules are being investigated to propose target therapies and increase patient survival.In the past decade, cancer stem cells (CSCs) have been identified as tumour-initiating cells. This subpopulation is resistant to cancer therapy such as chemo-and radiotherapies and successful treatments are dependent on the elimination of these cells (4). In addition, several reports highlight the interaction between CSCs and the immune system. 5109

show abstract

RETRACTED ARTICLE: Prognostic value of CD133 expression in cancer patients treated with chemoradiotherapy: a meta-analysis

Cited by 5 publications

References 36 publications

High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma

High CD133 Expression Is Associated with Worse Prognosis in Patients with Glioblastoma

Effect of CXCR4 and CD133 Co-expression on the Prognosis of Patients with Stage II~III Colon Cancer

Immunological and Clinical Impact of Cancer Stem Cells in Vulvar Cancer: Role of CD133/CD24/ABCG2-Expressing Cells

Contact Info

Product

Resources

About